Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.


Journal

Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617

Informations de publication

Date de publication:
14 10 2019
Historique:
received: 11 12 2017
revised: 03 04 2019
accepted: 13 08 2019
pubmed: 24 9 2019
medline: 26 5 2020
entrez: 24 9 2019
Statut: ppublish

Résumé

BCR-ABL1 point mutation-mediated resistance to tyrosine kinase inhibitor (TKI) therapy in Philadelphia chromosome-positive (Ph

Identifiants

pubmed: 31543464
pii: S1535-6108(19)30372-1
doi: 10.1016/j.ccell.2019.08.004
pmc: PMC6893878
mid: NIHMS1059932
pii:
doi:

Substances chimiques

BCR-ABL1 fusion protein, human 0
Imidazoles 0
Pyrazoles 0
Pyridazines 0
asciminib 0
Niacinamide 25X51I8RD4
ponatinib 4340891KFS
Fusion Proteins, bcr-abl EC 2.7.10.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

431-443.e5

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL082978
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA065823
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA049639
Pays : United States
Organisme : BLRD VA
ID : I01 BX000338
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA042014
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA178397
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Références

Cancer Cell. 2002 Aug;2(2):117-25
pubmed: 12204532
Leukemia. 2017 Dec;31(12):2844-2847
pubmed: 28819281
Blood. 2006 Oct 1;108(7):2332-8
pubmed: 16772610
Nature. 2017 Mar 30;543(7647):733-737
pubmed: 28329763
N Engl J Med. 2017 Mar 9;376(10):917-927
pubmed: 28273028
Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5507-12
pubmed: 18367669
Lancet Oncol. 2016 May;17(5):612-21
pubmed: 27083332
Ann Hematol. 2017 Apr;96(4):549-558
pubmed: 27686083
N Engl J Med. 2006 Jun 15;354(24):2531-41
pubmed: 16775234
Curr Hematol Malig Rep. 2015 Jun;10(2):158-66
pubmed: 25700679
N Engl J Med. 2006 Jun 15;354(24):2542-51
pubmed: 16775235
Cancer Res. 2013 Sep 15;73(18):5775-86
pubmed: 23887971
Nature. 2010 Jan 28;463(7280):501-6
pubmed: 20072125
Blood. 2019 Apr 4;133(14):1597-1606
pubmed: 30692122
Cancer Cell. 2014 Sep 8;26(3):428-442
pubmed: 25132497
Future Med Chem. 2011 Jan;3(1):29-43
pubmed: 21428824
Science. 2001 Aug 3;293(5531):876-80
pubmed: 11423618
J Clin Invest. 2007 Sep;117(9):2562-9
pubmed: 17710227
J Clin Oncol. 2015 Dec 10;33(35):4210-8
pubmed: 26371140
J Clin Invest. 2011 Jan;121(1):396-409
pubmed: 21157039
Cancer Cell. 2009 Nov 6;16(5):401-12
pubmed: 19878872
Cancer Res. 2012 Oct 1;72(19):4890-5
pubmed: 23002203
N Engl J Med. 2012 Nov 29;367(22):2075-88
pubmed: 23190221
Cancer Cell. 2012 Apr 17;21(4):577-92
pubmed: 22516264
Sci Transl Med. 2014 Sep 3;6(252):252ra121
pubmed: 25186176
Cancer Res. 2011 May 1;71(9):3189-95
pubmed: 21505103
Oncogene. 2003 Oct 20;22(47):7389-95
pubmed: 14576846
Blood. 2016 Feb 11;127(6):703-12
pubmed: 26603839
Blood. 2012 Jun 14;119(24):5621-31
pubmed: 22490804
Cell. 2003 Mar 21;112(6):859-71
pubmed: 12654251
Methods Enzymol. 2014;548:173-88
pubmed: 25399646
N Engl J Med. 2013 Nov 7;369(19):1783-96
pubmed: 24180494
PLoS One. 2015 Jun 15;10(6):e0130203
pubmed: 26075886
Blood. 2012 Feb 9;119(6):1501-10
pubmed: 22184410
Drugs. 2014 May;74(7):793-806
pubmed: 24807266
Blood. 2011 Oct 27;118(17):4567-76
pubmed: 21865346
Nat Rev Cancer. 2012 Jul 24;12(8):513-26
pubmed: 22825216

Auteurs

Christopher A Eide (CA)

OHSU Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, LBRB 513, Portland, OR 97239, USA; Howard Hughes Medical Institute, Portland, OR 97239, USA; Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR 97239, USA.

Matthew S Zabriskie (MS)

Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Room 4280, Salt Lake City, UT 84112, USA.

Samantha L Savage Stevens (SL)

OHSU Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, LBRB 513, Portland, OR 97239, USA; Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR 97239, USA.

Orlando Antelope (O)

Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Room 4280, Salt Lake City, UT 84112, USA.

Nadeem A Vellore (NA)

Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Room 4280, Salt Lake City, UT 84112, USA.

Hein Than (H)

Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Room 4280, Salt Lake City, UT 84112, USA.

Anna Reister Schultz (AR)

OHSU Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, LBRB 513, Portland, OR 97239, USA; Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR 97239, USA.

Phillip Clair (P)

Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Room 4280, Salt Lake City, UT 84112, USA.

Amber D Bowler (AD)

Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Room 4280, Salt Lake City, UT 84112, USA.

Anthony D Pomicter (AD)

Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Room 4280, Salt Lake City, UT 84112, USA.

Dongqing Yan (D)

Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Room 4280, Salt Lake City, UT 84112, USA.

Anna V Senina (AV)

Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Room 4280, Salt Lake City, UT 84112, USA.

Wang Qiang (W)

Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Room 4280, Salt Lake City, UT 84112, USA; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People's Republic of China.

Todd W Kelley (TW)

Department of Pathology, University of Utah, Salt Lake City, UT 84112, USA.

Philippe Szankasi (P)

ARUP Laboratories, Salt Lake City, UT 84108, USA.

Michael C Heinrich (MC)

OHSU Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, LBRB 513, Portland, OR 97239, USA; Portland VA Health Care System, Portland, OR, USA; Department of Cell, Developmental, & Cancer Biology, Oregon Health & Science University, Portland, OR 97239, USA.

Jeffrey W Tyner (JW)

OHSU Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, LBRB 513, Portland, OR 97239, USA; Department of Cell, Developmental, & Cancer Biology, Oregon Health & Science University, Portland, OR 97239, USA.

Delphine Rea (D)

Service d'Hematologie Adulte, INSERM UMR 1160, Hospital Saint-Louis, 75010 Paris, France.

Jean-Michel Cayuela (JM)

Laboratory of Hematology, University Hospital Saint-Louis, AP-HP and EA3518, University Paris Diderot, Paris, France.

Dong-Wook Kim (DW)

Leukemia Research Institute, The Catholic University of Korea, Seoul, Republic of Korea; Department of Hematology, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.

Cristina E Tognon (CE)

OHSU Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, LBRB 513, Portland, OR 97239, USA; Howard Hughes Medical Institute, Portland, OR 97239, USA; Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR 97239, USA.

Thomas O'Hare (T)

Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Room 4280, Salt Lake City, UT 84112, USA; Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT 84112, USA.

Brian J Druker (BJ)

OHSU Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, LBRB 513, Portland, OR 97239, USA; Howard Hughes Medical Institute, Portland, OR 97239, USA; Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR 97239, USA. Electronic address: drukerb@ohsu.edu.

Michael W Deininger (MW)

Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Room 4280, Salt Lake City, UT 84112, USA; Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT 84112, USA. Electronic address: michael.deininger@hci.utah.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH